Current and Future Directions in the Treatment of Metastatic Malignant Melanoma

Author(s): J. M. Baron, R. Heise, H. F. Merk, F. Abuzahra

Journal Name: Current Medicinal Chemistry - Anti-Cancer Agents
Continued as Anti-Cancer Agents in Medicinal Chemistry

Volume 3 , Issue 6 , 2003


Recently treatment strategies in advanced malignant melanoma have significantly changed. Due to high response rates (e.g. more than 50% for the Dartmouth-regimen), combination chemotherapy has been the standard therapy in several oncological and dermatooncological centers in the USA and Europe. For the last three years different prospective randomized phase III trials failed to achieve similar results. There was no benefit in overall survival and in response duration in comparison to single agent chemotherapy. Currently, randomized clinical trials seem to be the best approach for the clinical treatment of metastatic melanoma. In this review several novel strategies against malignant melanoma are discussed with focus on the role of single agent chemotherapy and biochemotherapy.

Keywords: metastatic melanoma, surgery, radiation therapy, single agent chemotherapy, combined chemotherapy, immunochemotherapy, radiosurgery

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [393 - 398]
Pages: 6
DOI: 10.2174/1568011033482224
Price: $65

Article Metrics

PDF: 2